Boston Scientific’s next stent
This article was originally published in The Gray Sheet
Executive Summary
FDA approves investigational device exemption for ATLAS clinical trial of the Taxus Liberté next-generation paclitaxel-eluting stent system. The prospective, single-arm study will enroll 822 patients at 60 sites in the U.S., Canada, Australia, New Zealand, Singapore, Hong Kong and Taiwan. A slow-release formulation of Liberté will be evaluated to show non-inferiority compared with a historical control (combined TAXUS IV and V studies), with an endpoint of nine-month target vessel revascularization...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.